SNT
Delivery · Highdata caveat$52M17mo
Syntara
Biotech · Haematology
Clinical-stage company targeting extracellular matrix dysfunction with amine oxidase chemistry, focused on therapies for myelofibrosis and MDS.
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$8.9M
Mar 2026 4C
Runway
17moADEQUATE
Based on Mar 2026 4C
Market Cap
$52M
Burn Rate
$1.6M/qtr
Mar 2026 4C
Shares Outstanding
2.1B
Pipeline Assets
3
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveCapital Raise13 May 2026
Share Purchase Plan Offer Booklet
$2.0MSpp·at$0.027
3M Price
SNT.ASX$0.025-16.7% 3M
Low $0.025High $0.034
Pipeline Assets (3)
Capital Raises & Buybacks
12mo dilution 21.4%12mo $10M3 raises
Current shares outstanding: 2.1B
Placement
SPP
2026-05-14spp
2026-04-29placement
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Substantial Holders (5%+ threshold)
1 noticearrow_drop_downD & A Holdings Limited
15.77%2026-05-11
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-05-28 · 4-day lag
Short position
0.00%
arrow_drop_down-0.11% over 6 reports
Shares short
0.0M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
Catalysts (11)· 5 upcoming · 6 past
EMA Orphan Drug Designation decision (MF)
UpcomingExpectedremoveMed30 June 2026
AZALOX interim data (high-risk MDS/CMML)
UpcomingExpectedremoveMed30 June 2026
Phase 2 MF combo (ruxolitinib) efficacy data readout
UpcomingExpectedarrow_upwardHigh30 June 2026
FDA feedback on myelofibrosis development plan
UpcomingTrack RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
High75/100(limited data)
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High83/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 3 of 3 guided dates· rolling 2yr· of 11 tracked
Filed 1 of 1 4Cs on time· statutory deadline· 1 filing without matched announcement
What drove these scores · rolling 2yr
arrow_drop_up
Burn reductions achieved — 1 quarter with >30% spend reduction
·
Amsulostat (SNT-5505) FDA — Positive FDA feedback for Amsulostat P2b trial — Delivered on time
·
Share Purchase Plan Offer Booklet — Delivered on time
·
Update - Proposed issue of securities - SNT — Delivered on time
·
Limited data adjustment — Score adjusted toward neutral (3/6 data points) — accuracy improves with more completed catalysts
Completed catalysts
✓Amsulostat (SNT-5505) FDA — Positive FDA feedback for Amsulostat P2b trial— The FDA provided positive feedback following a Type C meeting, supporting the proposed Phase 2b double-blind, placebo-controlled study design for amsulostat in myelofibrosis patients with inadequate response to JAK inhibitor therapy. This feedback enables Syntara to progress amsulostat into late-stage clinical development with an approximately 100-patient trial.
On time
✓Share Purchase Plan Offer Booklet
On time
✓Update - Proposed issue of securities - SNT
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(7)
1 activeClinicalTrials.gov ↗
Ph2Active Not RecruitingEnrollment stale · 945d
PXS-4728 (A)Matching Placebo (B)
Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder
REM Sleep Behavior Disorder
RandomizedQuadruple Blind50 Years – 80 Years
Primary endpoint To assess the reduction of microglial activation across striato-cortical regions
ENROL40
no manual snapshots — enter via record_enrollment.py
Announcements(20)
trending_up
Capital Raiseauto_awesome
Update - Proposed issue of securities - SNT14 May 2026
expand_more17KB